Financial results for the first half of 2009: significant investment in clinical programs and cash position reinforced
Start of the first Phase II clinical trial with monoclonal antibody IPH 2101 supported by a new 2.9 million euros financing from Oséo
Innate Pharma reports positive Phase IIa clinical results for IPH 1101 (γδT cell agonist) in type C viral hepatitis
Innate Pharma announces today the outcome of its annual general meeting, including changes in the composition of its Supervisory Board
Operational start of PLATINE, a joint immuno-monitoring platform
Innate Pharma to hold its Annual General Meeting of Shareholders on June 23, 2009, in Marseilles, France
Innate Pharma reports preliminary Phase I clinical data for IPH 2101 (a novel, anti-KIR monoclonal antibody activating NK cells) at the ASCO meeting
2008 Reference Document is available
Innate Pharma announces its turnover for the first quarter of 2009 and updates on its cash situation
Innate Pharma appoints Marcel Rozencweig, MD, as Senior Vice President, clinical and regulatory strategy
